Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MnB vaccine rLP8026 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Experimental (20ug); Active Comparator/Placebo |
| Cohort 2 | EXPERIMENTAL | Experimental (60ug); Active Comparator/Placebo |
| Cohort 3 | EXPERIMENTAL | Experimental (200ug); Active Comparator/Placebo |
| Name | Type | Description |
|---|---|---|
| MnB vaccine rLP8026 | BIOLOGICAL | MnB vaccine at 20ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively) |
Inclusion Criteria * Aged 18- to 36-months * Healthy male or female subjects Exclusion Criteria * Prior vaccination with a serogroup B meningococcal vaccine * Prior history of any invasive meningococcal disease
MnB vaccine rLP8026 is an investigational vaccine developed by Pfizer, Inc. for meningococcal B disease. It is a Phase 1 candidate that has been studied in healthy toddlers. The vaccine is designed to be given to young children, and its clinical program has focused on safety and immune response in that age group.
MnB vaccine rLP8026 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 study of the vaccine in healthy toddlers. The candidate is part of Pfizer's vaccine pipeline and has not been approved for commercial use.
MnB vaccine rLP8026 is in Phase 1 clinical development. It is an investigational vaccine and is not approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed for this candidate. The completed study enrolled 99 healthy toddlers in Australia.
MnB vaccine rLP8026 has been studied in one completed Phase 1 trial, NCT00387569, titled Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Healthy Toddlers. The trial enrolled 99 participants aged 18 months and older in Australia. It was randomized, double-blind, and controlled, and it enrolled healthy volunteers.
The Phase 1 trial of MnB vaccine rLP8026, NCT00387569, was a randomized, double-blind, controlled study in healthy toddlers. It enrolled 99 participants in Australia, with a minimum age of 18 months and no sex restriction. The study assessed safety and immunogenicity and has been completed.